AstraZeneca’s Imfinzi Scores Neoadjuvant/Adjuvant NSCLC Two-fer At AACR

AstraZeneca plc’s PD-L1 inhibitor Imfinzi (durvalumab) is one step closer to becoming a therapy both for neoadjuvant and adjuvant treatment of non-small cell lung cancer (NSCLC) with new data from the Phase III AEGEAN study at the American Association for Cancer Research annual meeting.

The positive results potentially sets it up as a competitor to Bristol Myers Squibb Company’s PD-1 inhibitor Opdivo (nivolumab), which in 2022 became the first to win US Food...